Arch Venture Management, Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$677.1M
Q ending 2026-03-31
Prior quarter
$651.7M
Q ending 2025-12-31
Change
+3.9% QoQ · +228.3% YoY
Positions
10
reported holdings
Largest positions
All 10 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Maze Therapeutics Inc | MAZE | Shares | $123.0M | 4.1M |
| Rapport Therapeutics Inc | RAPP | Shares | $116.7M | 3.7M |
| Vir Biotechnology Inc | VIR | Shares | $115.7M | 12.9M |
| Erasca Inc | ERAS | Shares | $114.7M | 7.1M |
| Beam Therapeutics Inc | BEAM | Shares | $108.2M | 4.5M |
| Lyell Immunopharma Inc | LYEL | Shares | $65.1M | 3.2M |
| Generate Biomedicines Inc | GENB | Shares | $24.3M | 1.9M |
| 10X Genomics Inc | TXG | Shares | $4.6M | 218K |
| Gossamer Bio Inc | GOSS | Shares | $2.6M | 8.1M |
| Q32 Bio Inc | QTTB | Shares | $2.1M | 320K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.